Kasey Bamel
Family · la Jolla, CANPI 1487106886
Payments from drug & device makers
Across 37 payments — averaging $246.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$7K
- AstraZeneca$365
- E.r. Squibb & Sons, L.L.C.$360
- Jazz Pharmaceuticals Inc.$279
- Johnson & Johnson$259
- Rigel Pharmaceuticals, Inc.$128
- plus $1K from 10 others
What the payments were for
- Consulting fees$7578%
- Speaking & faculty fees$5,29858%
- Travel & lodging$2953%
- Food & beverage$2,65929%
- Education$991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 15 | $6,623 |
| AstraZeneca | 3 | $365 |
| E.r. Squibb & Sons, L.L.C. | 3 | $360 |
| Jazz Pharmaceuticals Inc. | 3 | $279 |
| Johnson & Johnson | 2 | $259 |
| Rigel Pharmaceuticals, Inc. | 1 | $128 |
| Deciphera Pharmaceuticals Inc. | 1 | $125 |
| Gilead | 1 | $125 |
| Syndax Pharmaceuticals, Inc. | 1 | $121 |
| Kyowa Kirin, Inc. | 1 | $119 |
| Springworks Therapeutics, Inc. | 1 | $115 |
| Seagen Inc. | 1 | $106 |
| Foundation Medicine, Inc. | 1 | $105 |
| Amgen | 1 | $102 |
| Incyte Corporation | 1 | $99 |
| Astellas Pharma US Inc | 1 | $78 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,108 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 11 | $179,319 |
| EliquisApixaban | 18 | $10,389 |
| Ondansetron OdtOndansetron | 20 | $888 |
| Levothyroxine Sodium | 24 | $239 |
| Omeprazole | 24 | $191 |
| Triamcinolone Acetonide | 16 | $158 |
| LoperamideLoperamide Hcl | 12 | $150 |
| Prednisone | 16 | $107 |
| Gabapentin | 12 | $107 |
| Dexamethasone | 14 | $102 |
Paid to pharmacies, not to this prescriber.
Other family in la Jolla
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.